(Reuters) -U.S. drug regulators in November found quality control lapses at the Bloomington, Indiana factory of contract drug manufacturer Catalent, including discovery of a "pest" on the manufacturing line, according to an inspection report. Novo Holdings, the parent company of Novo Nordisk, on Monday announced it was buying Catalent in a $16.5 billion deal that included its Bloomington plant, which it plans to sell to Novo Nordisk to help it produce its popular weight-loss drug Wegovy. Catalent is already the main supplier of fill-finish work, or filling and packaging syringes an...